TDACU
Income statement / Annual
Last year (2023), Translational Development Acquisition Corp.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Translational Development Acquisition Corp.'s net income was -$485,550.00.
See Translational Development Acquisition Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
| Research and Development Expenses |
$0.00
|
$0.00
|
| General & Administrative Expenses |
$485,550.00
|
$70,662.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$485,550.00
|
$70,662.00
|
| Other Expenses |
$0.00
|
$0.00
|
| Operating Expenses |
$485,550.00
|
$70,662.00
|
| Cost And Expenses |
$485,550.00
|
$70,662.00
|
| Interest Income |
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$70,662.00
|
| EBITDA |
-$485,550.00 |
$0.00 |
| EBITDA Ratio |
0
|
0
|
| Operating Income Ratio |
0
|
0
|
| Total Other Income/Expenses Net |
-$485,550.00
|
$0.00
|
| Income Before Tax |
-$485,550.00
|
-$70,662.00
|
| Income Before Tax Ratio |
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
| Net Income |
-$485,550.00
|
-$70,662.00
|
| Net Income Ratio |
0
|
0
|
| EPS |
-0.12 |
-0.0174 |
| EPS Diluted |
-0.12 |
-0.0174 |
| Weighted Average Shares Out |
$4.05 M
|
$4.05 M
|
| Weighted Average Shares Out Diluted |
$4.05 M
|
$4.05 M
|
| Link |
|
|
